Evaluation of the clinical value of bone metabolic parameters for the screening of osseous metastases compared to bone scintigraphy

BMC Nuclear Medicine

Volumn 4, Issue , 2004, Pages

  Schoenberger, Johann ^a   Rozeboom, Silke ^a   Wirthgen Beyer, Eva ^a   Eilles, Christoph ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN DERIVATIVE;

ADULT; AGED; ARTICLE; BONE METABOLISM; BONE METASTASIS; BONE RADIOGRAPHY; BONE SCINTISCANNING; CARCINOMA; CELL ACTIVITY; CLINICAL EXAMINATION; COMPUTER ASSISTED TOMOGRAPHY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOBLAST; OSTEOCLAST; PROSPECTIVE STUDY; RADIOLOGY; SCREENING; SERUM;

EID: 12344250046     PISSN: 14712385     EISSN: None     Source Type: Journal    
DOI: 10.1186/1471-2385-4-3     Document Type: Article

References (16)

1. Galasko C: The anatomy and pathways of skeletal metastases. In In Bone metastases Edited by: Weiss L, Gilbert AH. Boston, MA: GK Hall; 1981:49-63.
2. Terranova PV, Hujanen ES, Martin G: Basement membrane and the invasive activity of metastatic tumor cells. J Natl Cancer Inst 1986, 77:311-316.
3. Prockop DJ, Kivirikko KI, Tuderman L, Guzman NA: The biosynthesis of collagen and its disorders. NEJM 1979, 301:13-23.
4. Koizumi M, Yamada Y, Takiguchi T, Nomura E, Furukawa M, Kitahara T, Yamashita T, Maede H, Takahashi S, Aiba K: Bone metabolic markers in bone metastases. J Cancer Res Clin Oncol 1995, 121(9-10):542-548.
5. Lorente JA, Morote J, Raventos C, Encabo G, Valenzuela H: Clinical efficacy of bone alkaline phosphatase and prostatic specific antigen in the diagnosis of bone metastasis in prostate cancer. J Urol 1996, 155:1348-1351.
6. Donohoe KJ, Henkin RE, Royal HD, Brown ML, Collier BD, O'Mara RE, Carretta RF: Procedure guideline for bone scintigraphy: 1.0. Society of Nuclear Medicine. JNM 1996, 37(11):1903-1906.
7. Krasnow AZ, Hellman RS, Timins ME, Collier D, Anderson T, Isitman AT: Diagnostic bone scanning in oncology. Semin Nucl Med 1997, 27:107-141.
8. Delmas PD: Biochemical markers of bone remodeling in osteoporosis. In In: Osteoporosis 96. International Congress, series 1118 Edited by: Papapoulos SE, Lips P, Pols HAP, Johnston CC, Delmas PD. Amsterdam: Elsevier; 1996:191-204.
9. Blomqvist C, Risteli I, Risteli J, Virkkunen P, Sarna S, Elomaa I: Markers of type I collagen degradation and synthesis in the monitoring of treatment response in bone metastases from breast carcinoma. Br J Cancer 1996, 73:1074-1079.
10. Yoshida K, Sumi S, Arai K, Koga F, Umeda H, Hosoya Y, Honda M, Yano M, Moriguchi H, Kitahara S: Serum concentration of type I collagen metabolites as a quantitative marker of bone metastases in patients with prostate cancer. Cancer 1997, 80:1760-1767.
11. Horiguchi T, Tachikawa S, Kondo R, Hirose M, Teruya S, Ishibashi A, Banno K: Usefulness of serum Carboxy-terminal telopeptide of type I collagen (ICTP= as a marker of bone metastases from lung cancer. Jpn J Clin Oncol 2000, 30(4):174-179.
12. Blomqvist C, Risteli L, Risteli J, Virkkunen P, Sarna S, Elomaa I: Markers of type I collagen degradation and synthesis in the monitoring of treatment response in bone metastases from breast carcinoma. Br J Cancer 1996, 73(9):1074-1079.
13. Wada N, Fujisaki M, Ishii S, Ikeda T, Kitajima M: Evaluation of bone metabolic markers in breast cancer with bone metastases. Breast Cancer 2001, 8(2):131-137.
14. Ulrich U, Rhiem K, Schmolling J, Flaskamp C, Paffenholz I, Salzer H, Bauknecht T, Schlebusch H: Cross-linked type I collagen C- and N-telopeptides in women with bone metastases from breast cancer. Arch Gynecol Obstet 2001, 264(4):186-190.
15. Koizumi M, Matsumoto S, Takahashi S, Yamashita T, Etsuro O: Bone metabolic markers in the evaluation of bone scan flare phenomenon in bone metastases of breast cancer. Clin Nucl Med 1999, 24(1):15-20.
16. Aman S, Paimela L, Leirisalo-Repo M, Risteli J, Kautiainen H, Helve T, Hakala M: Prediction of disease progression in early rheumatoid arthritis by ICTP, RF and CRP. A comparative 3-year follow-up study. Rheumatology 2000, 39:1009-1013.